Danish Pharmacovigilance Update 28 November 2013

03 February 2014

In this issue of Danish Pharmacovigilance Update:

News from the EU

  • Acipimox (Olbetam®) should only be used to lower triglycerides when other treatments of dyslipidaemia are not sufficient
  • Risk of blood clots from the use of the cancer medicine ponatinib (Iclusig®)
  • All patients should be screened for hepatitis B virus (HBV) before starting treatment with rituximab (Mabthera®)
  • Preparation error resulting in overdose of cabazitaxel (Jevtana)

News from the Danish Health and Medicines Authority

  • Ciprofloxacin and the risk of tendon disorders
  • Decrease in the use of medicines for the treatment of anogenital warts in adolescents under the age of 20
  • Bisphosphonates/denosumab and the risk of osteonecrosis of the jaw
  • The tugboats of preventive health – an article from the Danish weekly newspaper Weekendavisen

Short news

  • Batches of the NovoMix®30 FlexPen® recalled
  • Reporting of adverse reactions to the Danish Health and Medicines Authority
  • Danish Pharmacovigilance Update celebrates its 4th anniversary

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.